Pharmexa grants PADRE license to ImmunoVaccine Technologies Inc.


Pharmexa has entered into a license agreement with ImmunoVaccine Technologies Inc. (IVT) of Halifax, Nova Scotia for the use of PADRE® immunostimulatory peptide(s) with IVT's VacciMax® vaccines. IVT has a non-exclusive right to use PADRE® in combination with up to three different targets for its vaccines. The agreement includes up-front and future payments as well as royalties on sales. Financial details were not disclosed and the agreement will not effect Pharmexa's financial forecasts for 2006.

The PADRE® peptides are a family of proprietary synthetic molecules that are potent, "universal" stimulators of helper T cells. When combined with vaccines, PADRE® potentiates both the humoral and cellular immune responses to the vaccine. PADRE® is an integral component of some of Pharmexa's vaccines in cancer and infectious diseases and was acquired as part of the assets purchased from IDM Pharma resulting in the formation of Pharmexa-Epimmune based in San Diego, California.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances